Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Current Deferred Revenue (2019 - 2025)

Historic Current Deferred Revenue for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $22.6 million.

  • Legend Biotech's Current Deferred Revenue fell 6425.64% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.6 million, marking a year-over-year decrease of 6425.64%. This contributed to the annual value of $46.9 million for FY2024, which is 1157.52% down from last year.
  • As of Q3 2025, Legend Biotech's Current Deferred Revenue stood at $22.6 million, which was down 6425.64% from $33.2 million recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Current Deferred Revenue peaked at $245.8 million during Q1 2022, and registered a low of -$60.6 million during Q4 2021.
  • For the 5-year period, Legend Biotech's Current Deferred Revenue averaged around $63.0 million, with its median value being $46.9 million (2024).
  • As far as peak fluctuations go, Legend Biotech's Current Deferred Revenue surged by 9647141.93% in 2021, and later plummeted by 6425.64% in 2025.
  • Quarter analysis of 5 years shows Legend Biotech's Current Deferred Revenue stood at -$60.6 million in 2021, then skyrocketed by 505.4% to $245.8 million in 2022, then tumbled by 78.44% to $53.0 million in 2023, then decreased by 11.58% to $46.9 million in 2024, then tumbled by 51.84% to $22.6 million in 2025.
  • Its last three reported values are $22.6 million in Q3 2025, $33.2 million for Q2 2025, and $39.5 million during Q1 2025.